Cover Image
市場調查報告書

全球癌症免疫治療藥市場趨勢,機會分析,市場佔有率,預測

Global Cancer Immunotherapy Drugs Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 374053
出版日期 內容資訊 英文 140 Pages
商品交期: 請詢問到貨日
價格
Back to Top
全球癌症免疫治療藥市場趨勢,機會分析,市場佔有率,預測 Global Cancer Immunotherapy Drugs Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022
出版日期: 2016年10月01日 內容資訊: 英文 140 Pages
簡介

本報告提供全球癌症免疫治療藥市場相關調查,市場概要與趨勢,各分類市場,各地區趨勢,並彙整主要企業的簡介等資訊。

第1章 簡介

第2章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 指標分析
  • 市場趨勢
  • 競爭環境
  • 波特五力分析模式
  • 主要的購買標準
  • 策略性建議
  • 策略性結論

第3章 市場決策因素

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會
  • 市場課題

第4章 部門分析

  • 親市場
  • 競爭市場/替代市場

第5章 市場區隔

  • 各產品

第6章 各地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第7章 企業簡介

目錄
Product Code: HAD-3461016

The global cancer immunotherapy market is expected to reach $119.39 Billion by 2022 from $61.9 Billion in 2014, at a CAGR of 14.0% during 2016 to 2022. Factors such as increasing incidence of cancer and rising healthcare expenditure are driving the growth of this market.

The major driver for the global cancer immunotherapy market is increasing prevalence of cancer.

In 2016, estimation of cancer cases are 1,685,210 which are diagnosed in USA and around 595,690 people will die from cancer .The number of people living beyond the cancer diagnosis reached nearly $14.5 million in 2014 and expected to rise to almost 18 million in year 2022. National expenditures for cancer care in USA could reach up to $157 Billion by 2022. By year 2030, the new breast cancer cases in females in USA are estimated to increase about 441,000 that accounts incremental by 50% as per today. The percentage of new cancer cases of women falling in ages 70-84 is expecting to increase from 24% to 35%. By the end of year 2022, expected number of new cancer cases in the USA will rise about 25% in men which would be more than $1 million cases per year, and by about 22% in women that to be more than 900,000 cases per year. By 2016, among children, an estimation of 10,380 are to be diagnosed with cancer and 1,250 will die from it

The global cancer immunotherapy market has been segmented based on type, application, and end user. On the basis of type, the market has been segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immune modulators. The monoclonal antibodies segment is expected to account for the largest share of the market in 2016, while the checkpoint inhibitors segment is projected to witness the highest CAGR during 2016 to 2022. The high growth in this segment is primarily attributed to the high success rate of these inhibitors. On the basis of applications, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others. The lung cancer segment is expected to grow at the highest CAGR during the forecast period. The high growth in this segment can be attributed to the increasing prevalence of this type of cancer and rising demand for advanced treatment options. On the basis of end users, the global cancer immunotherapy market is segmented into hospitals and clinics & others. The rise in healthcare spending has resulted in the increasing use of immunotherapeutic drugs in hospitals

North America dominates the cancer immunotherapy market in 2016, owing to the growing aging population and the increased funding from government and non-government agencies in order to increase the research capacity. However, the RoW region is expected to witness the highest CAGR during the forecast period. The high growth in this segment is centered at Latin America, the Middle East, and Africa.

The major players in this market include Amgen, AstraZeneca, F. Hoffman La-Roche Ltd., Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company , Janssen Global Services, LLC , Merck,Novartis and Pfizer . Acquisitions, Mergers and key players are key strategies for any market to grow. In May 2016, Pfizer Inc. and Anacor Pharmaceuticals, Inc have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value of approximately $5.2 billion.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2 ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. MARKET DEFINITION AND SCOPE
  • 2.2. KEY FINDINGS
  • 2.3. PARAMETRIC TECHNOLOGIES
    • 2.3.1. RAW MATERIAL SUPPLIER
    • 2.3.2. PRODUCTION GEOGRAPHICALLY
    • 2.3.3. ADOPTION ACROSS VARIOUS INDUSTRIES
  • 2.4. KEY MARKET INSIGHTS
    • 2.4.1. TOP EMERGING COUNTRIES
    • 2.4.2. TOP REVENUE GENERATING SEGMENTS
    • 2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
  • 2.5. COMPETITIVE LANDSCAPE
    • 2.5.1. MARKET SHARE TECHNOLOGIES
    • 2.5.2. TOP WINNING STRATEGIES
    • 2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
  • 2.6. PORTER'S FIVE FORCE MODEL
    • 2.6.1. THREAT OF NEW ENTRANTS
    • 2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 2.6.3. BARGAINING POWER OF BUYER
    • 2.6.4. BARGAINING POWER OF SUPPLIER
    • 2.6.5. INTENSITY OF COMPETITIVE RIVALRY
  • 2.7. KEY BUYING CRITERIA
  • 2.8. STRATEGIC RECOMMENDATION
  • 2.9. STRATEGIC CONCLUSIONS

3 MARKET DETERMINANTS

  • 3.1 MARKET DRIVERS
    • 3.1.1. IMMUNOTHERAPY OF CANCER IS MORE EFFECTIVE THEN TRADITIONAL THERAPY
    • 3.1.2. REDUCTION IN OVERALL TIMELINE AND COST OF DRUG DISCOVERY
    • 3.1.3. FAST TRACK AND ORPHAN DRUG DESTINATIONS
    • 3.1.4. RISE IN INCIDENCE RATE OF CANCER WORLDWIDE
    • 3.1.5. DEVELOPMENT OF BIOINFORMATICS TOOLS ARE ENHANCING DRUG DEVELOPMENT PROCESS
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. HIGH COST OF CANCER IMMUNOTHERAPY TREATMENT
    • 3.2.2.HIGH ATTRITION RATE IN PRODUCT DEVELOPMENT CYCLE
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. SIGNIFICANT GROWTH PROSPECTS IN DEVELOPING COUNTRIES
    • 3.3.2. IMMUNOTHERAPY TO REPLACE CHEMOTHERAPY AS FIRST LINE THERAPY
    • 3.3.3. INCREASE IN CLINICAL TRIALS AGAINST SEVERAL TYPES OF CANCERS IN IMMUNOTHERAPY
  • 3.4. MARKET CHALLENGES
    • 3.4.1.TOP SELLING BIOLOGICS WITH LESS PATENT EXPIRATION
    • 3.4.2. AVAILABILITY OF LIMITED FUNDS TO INITIATE CLINICAL TRIAL
    • 3.4.3. COMPLEXITY OF CANCER MAY LIMIT THE IMMUNE RESPONSE

4 SECTOR ANALYSIS

  • 4.1 PARENT MARKET
  • 4.2 COMPETITORS MARKET/ ALTERNATIVE MARKET

5 MARKET SEGMENTATION

  • 5.1 BY PRODUCT TYPE
    • 5.1.1 GLOBAL CANCER IMMUNOTHERAPY MARKET BY MONOCLONAL ANTIBIOTIC 2014-2022($MILLION)
      • 5.1.1.1 GLOBAL CANCER IMMUNOTHERAPY MARKET BY NAKED MONOCLONAL ANTIBIOTICS 2014-2022 ($MILLION)
      • 5.1.1.2 GLOBAL CANCER IMMUNOTHERAPY MARKET BY CONJUGATED MONOCLONAL ANTIBIOTICS2014-2022 ($MILLION)
      • 5.1.1.3 GLOBAL CANCER IMMUNOTHERAPY MARKET BY BISPECIFIC MONOCLONAL ANTIBIOTICS 2014-2022 ($MILLION)
    • 5.1.2 GLOBAL CANCER IMMUNOTHERAPY MARKET BY INTERFERON'S 2014-2022 ($MILLION)
      • 5.1.2.1 GLOBAL CANCER IMMUNOTHERAPY MARKET BY PROPHYLACTIC VACCINES 2014-2022 ($MILLION)
      • 5.1.2.2 GLOBAL CANCER IMMUNOTHERAPY MARKET BY THERAPEUTIC VACCINES 2014-2022 ($MILLION)
    • 5.1.3 GLOBAL CANCER IMMUNOTHERAPY MARKET BY CHECKPOINTS INHIBITORS 2014-2022 ($MILLION)
      • 5.1.3.1 GLOBAL CANCER IMMUNOTHERAPY MARKET BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 2014-2022 ($MILLION)
      • 5.1.3.2 GLOBAL CANCER IMMUNOTHERAPY MARKET BY PROGRAMMED DEATH 1 (PD-1) AND PROGRAMMED DEATH LIGAND 1 (PD-L1) 2014-2022 ($MILLION)
    • 5.1.4 GLOBAL CANCER IMMUNOTHERAPY MARKET BY CELL THERAPIES 2014-2022 ($MILLION)
      • 5.1.4.1 GLOBAL CANCER IMMUNOTHERAPY MARKET BY CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 2014-2022 ($MILLION)
      • 5.1.4.2 GLOBAL CANCER IMMUNOTHERAPY MARKET BY DENDRITIC CELLS 2014-2022 ($MILLION)
    • 5.1.5 GLOBAL CANCER IMMUNOTHERAPY MARKET BY IMMUNO MODULATORS 2014-2022 ($MILLION)
      • 5.1.5.1 GLOBAL CANCER IMMUNOTHERAPY MARKET BY GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF & G-CSF) 2014-2022 ($MILLION)
      • 5.1.5.2 GLOBAL CANCER IMMUNOTHERAPY MARKET BY INTERFERON'S (IFN) 2014-2022 ($MILLION)
      • 5.1.5.3 GLOBAL CANCER IMMUNOTHERAPY MARKET BY INTERLEUKINS (IL) 2014-2022 ($MILLION)
      • 5.1.5.4 GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS 2014-2022 ($MILLION)
        • 5.1.5.4.1 GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS IMMUNOTHERAPY 2014-2022 ($MILLION)
        • 5.1.5.4.2 GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS IMMUNITY AS AN OBSTACLE 2014-2022 ($MILLION)
        • 5.1.5.4.3 GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS IMMUNITY AS AN ALLY 2014-2022 ($MILLION)
        • 5.1.5.4.4 GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS APPROVED PRODUCTS & CLINICAL TRIALS 2014-2022 ($MILLION)

4 GEOGRAPHIC ANALYSIS

  • 4.1 NORTH AMERICA CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.1.1 UNITED STATES (US) CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.1.2 CANADA CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
  • 4.2 EUROPE CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.2.1 UNITED KINGDOM (UK) CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.2.2 FRANCE CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.2.3 GERMANY CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.2.4 SPAIN CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.2.5 ITALY CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.2.6 ROE MARKET 2014-2022 ($MILLION)
    • 4.2.7 AUSTRIA MARKET 2014-2022 ($MILLION)
  • 4.3 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.3.1 INDIA CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.3.2 CHINA CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.3.3 JAPAN CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.3.4 KOREA CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.3.5 AUSTRALIA CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.3.6 ROAPAC CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
  • 4.4 REST OF THE WORLD CANCER IMMUNOTHERAPY MARKET 2014-2022($MILLION)
    • 4.4.1 LATIN AMERICA CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.4.2 BRAZIL CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)
    • 4.4.3 MEXICO CANCER IMMUNOTHERAPY MARKET 2014-2022 ($MILLION)

6. COMPANY PROFILE: - (OVER, SCOT, TECHNOLOGIES, STRATEGIC REVIEW)

  • 1. F. HOFFMANN-LA ROCHE AG
  • 2. MERCK & CO., INC.
  • 3. NOVARTIS INTERNATIONAL AG
  • 4. GLAXOSMITHKLINE PLC
  • 5. AMGEN INC.
  • 6. CELGENE CORPORATION
  • 7. SEATTLE GENETICS, INC.
  • 8. SPECTRUM PHARMACEUTICALS, INC.
  • 9. AMGEN INC.
  • 10. ASTRAZENECA
  • 11. BAYER AG
  • 12. BRISTOL-MYERS SQUIBB
  • 13. ELI LILLY AND COMPANY
  • 14. JANSSEN GLOBAL SERVICES, LLC (JOHNSON AND JOHNSON)
  • 15. PFIZER

LIST OF TABLE

  • 1. GLOBAL CANCER IMMUNOTHERAPY MARKET BY PRODUCT TYPE 2016 -2021 ($MILLION)
  • 2. GLOBAL CANCER IMMUNOTHERAPY MARKET BY MONOCLONAL ANTIBIOTICS 2014-2022 ($MILLION)
  • 3. GLOBAL CANCER IMMUNOTHERAPY MARKET BY NAKED MONOCLONAL ANTIBIOTICS 2014-2022 ($MILLION)
  • 4. GLOBAL CANCER IMMUNOTHERAPY MARKET BY CONJUGATED MONOCLONAL ANTIBIOTICS 2014-2022 ($MILLION)
  • 5. GLOBAL CANCER IMMUNOTHERAPY MARKET BY BISPECIFIC MONOCLONAL ANTIBIOTICS 2014-2022 ($MILLION)
  • 6. GLOBAL CANCER IMMUNOTHERAPY MARKET BY INTERFERON'S 2014-2022 ($MILLION)
  • 7. GLOBAL CANCER IMMUNOTHERAPY MARKET BY PROPHYLACTIC VACCINES 2014-2022 ($MILLION)
  • 8. GLOBAL CANCER IMMUNOTHERAPY MARKET BY THERAPEUTIC VACCINES 2014-2022 ($MILLION)
  • 9. GLOBAL CANCER IMMUNOTHERAPY MARKET BY CHECKPOINTS INHIBITORS 2014-2022 ($MILLION)
  • 10. GLOBAL CANCER IMMUNOTHERAPY MARKET BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 2014-2022 ($MILLION)
  • 11. GLOBAL CANCER IMMUNOTHERAPY MARKET BY PROGRAMMED DEATH 1 (PD-1) AND PROGRAMMED DEATH LIGAND 1 (PD-L1) 2014-2022 ($MILLION)
  • 12. GLOBAL CANCER IMMUNOTHERAPY MARKET BY CELL THERAPIES 2014-2022 ($MILLION)
  • 13. GLOBAL CANCER IMMUNOTHERAPY MARKET BY CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 2014-2022 ($MILLION)
  • 14. GLOBAL CANCER IMMUNOTHERAPY MARKET BY DENDRITIC CELLS 2014-2022 ($MILLION)
  • 15. GLOBAL CANCER IMMUNOTHERAPY MARKET BY IMMUNOMODULATORS 2014-2022 ($MILLION)
  • 16. GLOBAL CANCER IMMUNOTHERAPY MARKET BY GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF & G-CSF) 2014-2022 ($MILLION)
  • 17. GLOBAL CANCER IMMUNOTHERAPY MARKET BY INTERFERON'S (IFN) 2014-2022 ($MILLION)
  • 18. GLOBAL CANCER IMMUNOTHERAPY MARKET BY INTERLEUKINS (IL) 2014-2022 ($MILLION)
  • 19. GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS 2014-2022 ($MILLION)
  • 20. GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS IMMUNOTHERAPY 2014-2022 ($MILLION)
  • 21. GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS IMMUNITY AS AN OBSTACLE 2014-2022 ($MILLION)
  • 22. GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS IMMUNITY AS AN ALLY2014-2022 ($MILLION)
  • 23. GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS APPROVED PRODUCTS & CLINICAL TRIALS 2014-2022 ($MILLION)

LIST OF FIGURES

  • 1. GLOBAL CANCER IMMUNOTHERAPY MARKET BY PRODUCT TYPE 2014 -2022($MILLION)
  • 2. GLOBAL CANCER IMMUNOTHERAPY MARKET BY MONOCLONAL ANTIBIOTICS 2014-2022 ($MILLION)
  • 3. GLOBAL CANCER IMMUNOTHERAPY MARKET BY NAKED MONOCLONAL ANTIBIOTICS 2014-2022 ($MILLION)
  • 4. GLOBAL CANCER IMMUNOTHERAPY MARKET BY CONJUGATED MONOCLONAL ANTIBIOTICS 2014-2022 ($MILLION)
  • 5. GLOBAL CANCER IMMUNOTHERAPY MARKET BY BISPECIFIC MONOCLONAL ANTIBIOTICS 2014-2022 ($MILLION)
  • 6. GLOBAL CANCER IMMUNOTHERAPY MARKET BY INTERFERON'S 2014-2022 ($MILLION)
  • 7. GLOBAL CANCER IMMUNOTHERAPY MARKET BY PROPHYLACTIC VACCINES 2014-2022 ($MILLION)
  • 8. GLOBAL CANCER IMMUNOTHERAPY MARKET BY THERAPEUTIC VACCINES 2014-2022 ($MILLION)
  • 9. GLOBAL CANCER IMMUNOTHERAPY MARKET BY CHECKPOINTS INHIBITORS 2014-2022 ($MILLION)
  • 10. GLOBAL CANCER IMMUNOTHERAPY MARKET BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 2014-2022 ($MILLION)
  • 11. GLOBAL CANCER IMMUNOTHERAPY MARKET BY PROGRAMMED DEATH 1 (PD-1) AND PROGRAMMED DEATH LIGAND 1 (PD-L1) 2014-2022 ($MILLION)
  • 12. GLOBAL CANCER IMMUNOTHERAPY MARKET BY CELL THERAPIES 2014-2022 ($MILLION)
  • 13. GLOBAL CANCER IMMUNOTHERAPY MARKET BY CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 2014-2022 ($MILLION)
  • 14. GLOBAL CANCER IMMUNOTHERAPY MARKET BY DENDRITIC CELLS 2014-2022 ($MILLION)
  • 15. GLOBAL CANCER IMMUNOTHERAPY MARKET BY IMMUNOMODULATORS 2014-2022 ($MILLION)
  • 16. GLOBAL CANCER IMMUNOTHERAPY MARKET BY GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF & G-CSF) 2014-2022 ($MILLION)
  • 17. GLOBAL CANCER IMMUNOTHERAPY MARKET BY INTERFERON'S (IFN) 2014-2022 ($MILLION)
  • 18. GLOBAL CANCER IMMUNOTHERAPY MARKET BY INTERLEUKINS (IL) 2014-2022 ($MILLION)
  • 19. GLOBAL CANCER IMMUNOTHERAPY MARKET BY ONCOLYTIC VIRUS 2014-2022 ($MILLION)
Back to Top